ライフサイエンスコーパス: proliferative diabetic retinopathy

1 sis that occurs in blinding diseases such as proliferative diabetic retinopathy.

2 nd that this change can precede the onset of proliferative diabetic retinopathy.

3 ctomy is performed in treating patients with proliferative diabetic retinopathy.

4 se with moderately severe to very severe non proliferative diabetic retinopathy.

5 eased in the vitreous fluid of patients with proliferative diabetic retinopathy.

6 safety of combined surgery in patients with proliferative diabetic retinopathy.

7 sive neovascularization in the retina causes proliferative diabetic retinopathy.

8 lly relevant to the angiogenesis observed in proliferative diabetic retinopathy.

9 ization of ischemic retinal diseases such as proliferative diabetic retinopathy.

10 patients over 60 years of age or those with proliferative diabetic retinopathy.

11 e with neovacularizations is the hallmark of proliferative diabetic retinopathy.

12 such as age-related macular degeneration and proliferative diabetic retinopathy.

13 nonclearing vitreous hemorrhage secondary to proliferative diabetic retinopathy.

14 permeability that are characteristic of non-proliferative diabetic retinopathy.

15 ACCORD trial participants with no history of proliferative diabetic retinopathy.

16 agents also provide therapeutic benefits in proliferative diabetic retinopathy.

17 ents broadens therapeutic options for PRP in proliferative diabetic retinopathy.

18 eatment for reducing severe visual loss from proliferative diabetic retinopathy.

19 at least through 2 years, for patients with proliferative diabetic retinopathy.

20 rence of neovascularization in patients with proliferative diabetic retinopathy.

21 betic retinopathy (diabetic macular edema or proliferative diabetic retinopathy), 17 trials (23%) inc

22 dergone cataract surgery (39.9%), those with proliferative diabetic retinopathy (25.7%), and those wi

23 ferative diabetic retinopathy (NPDR), 15 had proliferative diabetic retinopathy, 7 had retinal detach

24 cluding 0.9% of all injections that were for proliferative diabetic retinopathy), 8.3% to treat retin

25 Patients with proliferative diabetic retinopathy, a history of intravi

26 thology related to both nonproliferative and proliferative diabetic retinopathy and age-related macul

27 and other pathological conditions, including proliferative diabetic retinopathy and age-related macul

28 ion and ocular permeability are hallmarks of proliferative diabetic retinopathy and age-related macul

29 meability contributes to the pathogenesis of proliferative diabetic retinopathy and diabetic macular

30 reatening diabetic retinopathy that includes proliferative diabetic retinopathy and diabetic macular

31 herapy is a useful tool in the management of proliferative diabetic retinopathy and diabetic macular

32 including age-related macular degeneration, proliferative diabetic retinopathy and glaucomatous opti

33 udies related to retinopathy of prematurity, proliferative diabetic retinopathy and in studies evalua

34 ear, however, how PlGF, which is elevated in proliferative diabetic retinopathy and is a VEGF homolog

35 mediator of aberrant retinal angiogenesis in proliferative diabetic retinopathy and its modulation ha

36 Prevalence and incidence of proliferative diabetic retinopathy and macular edema.

37 serum lipids or statins on the incidence of proliferative diabetic retinopathy and macular edema.

38 In diseases such as proliferative diabetic retinopathy and neovascular age-r

39 and is an excellent target for treatment of proliferative diabetic retinopathy and other ischemic re

40 angiogenesis and vascular remodeling during proliferative diabetic retinopathy and other ischemic re

41 D) occurs in approximately 5% of people with proliferative diabetic retinopathy and poses a threat to

42 n the retina that underlies the pathology of proliferative diabetic retinopathy and retinopathy of pr

43 scularization, which underlies diseases like proliferative diabetic retinopathy and retinopathy of pr

44 numerous angiogenesis-based diseases such as proliferative diabetic retinopathy and solid tumors.

45 d in the serum and vitreous of patients with proliferative diabetic retinopathy and that smooth muscl

46 actor (IGF) biological activity increases in proliferative diabetic retinopathy and that this activit

47 change is more accentuated in patients with proliferative diabetic retinopathy and vitreous hemorrha

48 d with a variety of human diseases including proliferative diabetic retinopathy and wet age-related m

49 idated scale from stage 0 (none) to stage 4 (proliferative diabetic retinopathy), and percentage of t

50 ith Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy), and Protocol T (A C

51 lmark of the early stage of the disease, non-proliferative diabetic retinopathy, and can be detected

52 from patients with type 2 diabetes mellitus, proliferative diabetic retinopathy, and concomitant reti

53 vitreous of patients with complications from proliferative diabetic retinopathy, and correlate with I

54 sening of diabetic retinopathy, incidence of proliferative diabetic retinopathy, and incidence of mac

55 ty factor is a likely angiogenic mediator in proliferative diabetic retinopathy, and its role is unde

56 nti-VEGF drugs in DME is not as robust as in proliferative diabetic retinopathy, and many patients wi

57 Leptin in human vitreous is elevated in proliferative diabetic retinopathy, and retinal detachme

58 went vitrectomy for complications related to proliferative diabetic retinopathy, and the other 13 for

59 diseases such as retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related

60 ients with diabetic macular edema, severe or proliferative diabetic retinopathy, and with history of

61 4 patients undergoing primary vitrectomy for proliferative diabetic retinopathy at 16 different vitre

62 (DME) at baseline, were less likely to have proliferative diabetic retinopathy at baseline, received

63 ks and benefits of pars plana vitrectomy for proliferative diabetic retinopathy, but clinical trial d

64 generating tractional forces associated with proliferative diabetic retinopathy can arise from Muller

65 Vitreous hemorrhage from proliferative diabetic retinopathy can cause loss of vis

66 nd Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy (CLARITY) trial was c

67 r progression of retinopathy, progression to proliferative diabetic retinopathy, clinically significa

68 55; 95% CI, 1.32-1.82), as did patients with proliferative diabetic retinopathy (CVA: HR, 2.53; 95% C

69 they had a history of proliferative disease (proliferative diabetic retinopathy), diabetic macular ed

70 75% (n=155) had non-proliferative diabetic retinopathy during the onset of D

71 nducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between Febr

72 nducted at 55 US sites among 305 adults with proliferative diabetic retinopathy enrolled between Febr

73 range of prevalent ocular diseases including proliferative diabetic retinopathy, exudative age-relate

74 des clinically significant macular edema and proliferative diabetic retinopathy, following cataract s

75 risk of severe vision loss in patients with proliferative diabetic retinopathy for the past four dec

76 Proliferative diabetic retinopathy has been managed by p

77 Eyes with proliferative diabetic retinopathy have a variable respo

78 separate studies reported that patients with proliferative diabetic retinopathy have increased serum

79 period was associated with the incidence of proliferative diabetic retinopathy (hazard ratio [HR], 1

80 mimic the phenotype of nonproliferative and proliferative diabetic retinopathy in humans.

81 which can lead to diabetic macular edema and proliferative diabetic retinopathy in the eye.

82 statistically significant increased risk for proliferative diabetic retinopathy in the multivariate m

83 There was an elevated risk of proliferative diabetic retinopathy in the OSA cohort at

84 athy as defined by diabetic macular edema or proliferative diabetic retinopathy in unrelated cases as

85 Amongst those with diabetes, the presence of proliferative diabetic retinopathy increased the likelih

86 , anecdotal evidence has long suggested that proliferative diabetic retinopathy is rarely associated

87 Proliferative diabetic retinopathy is the most common ca

88 zed broadly as proliferation, exemplified by proliferative diabetic retinopathy, leakage such as macu

89 hms for diabetic vitreous hemorrhage and non-proliferative diabetic retinopathy may be influenced by

90 es, patients aged <= 60 years and those with proliferative diabetic retinopathy may necessitate caref

91 ed in investigator-initiated trials studying proliferative diabetic retinopathy, neovascular age-rela

92 In addition, non-proliferative diabetic retinopathy (NPDR) and proliferat

93 hy (PDR) development among patients with non-proliferative diabetic retinopathy (NPDR) in US real-wor

94 Non proliferative diabetic retinopathy (NPDR) was found in 6

95 s, including 10 individuals with DME and non-proliferative diabetic retinopathy (NPDR), 13 with DME,

96 0 patients with diabetes, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had pr

97 three with moderate, and two with severe non-proliferative diabetic retinopathy (NPDR).

98 inal blood flow and oxygen metabolism in non-proliferative diabetic retinopathy (NPDR).

99 ormalities in diabetic patients who have non-proliferative diabetic retinopathy (NPDR).

100 ts with no diabetic retinopathy and with non-proliferative diabetic retinopathy (NPDR).

101 tein cholesterol and decreased prevalence of proliferative diabetic retinopathy (odds ratio per 10 mg

102 Fundus examination showed moderate non-proliferative diabetic retinopathy of both eyes with sca

103 y [NPDR]; 22 moderate NPDR; 9 severe NPDR; 5 proliferative diabetic retinopathy) of 40 diabetic patie

104 Overall, the probability of progression to proliferative diabetic retinopathy or clinically signifi

105 e risk of progression from no retinopathy to proliferative diabetic retinopathy or clinically signifi

106 o determine the likelihood of progression to proliferative diabetic retinopathy or clinically signifi

107 defined by prior laser treatment for either proliferative diabetic retinopathy or diabetic macular e

108 density lipoprotein cholesterol and incident proliferative diabetic retinopathy or macular edema, nor

109 or of statin use with decreased incidence of proliferative diabetic retinopathy or macular edema, wer

110 pregnancy was not associated with higher non-proliferative diabetic retinopathy or proliferative diab

111 ns were especially elevated in patients with proliferative diabetic retinopathy or retinal detachment

112 Eyes with proliferative diabetic retinopathy or severe nonprolifer

113 aged <= 60 years (p < 0.001), and those with proliferative diabetic retinopathy (p < 0.001).

114 ere NPDR, 4.8% for severe NPDR, and 5.1% for proliferative diabetic retinopathy; P < 0.001), hemoglob

115 AID demonstrated a significant effect in non-proliferative diabetic retinopathy patients.

116 presumed ocular histoplasmosis syndrome (6), proliferative diabetic retinopathy (PDR) (5), epiretinal

117 Patients with proliferative diabetic retinopathy (PDR) (ICD-10 H10.35/

118 ts who underwent fundus examination, 60% had proliferative diabetic retinopathy (PDR) and 32% had dia

119 5 individuals with type 1 or 2 diabetes with proliferative diabetic retinopathy (PDR) and 61 individu

120 s samples from 20 diabetic patients: 13 with proliferative diabetic retinopathy (PDR) and 7 with diab

121 e diagnosis of diabetes to sight-threatening proliferative diabetic retinopathy (PDR) and diabetic ma

122 Effective management of proliferative diabetic retinopathy (PDR) and diabetic ma

123 diabetic retinopathy (NPDR) and DME, 38 had proliferative diabetic retinopathy (PDR) and DME, 101 ha

124 nolone acetonide (FAc) on the progression to proliferative diabetic retinopathy (PDR) and the impact

125 ine the time and risk factors for developing proliferative diabetic retinopathy (PDR) and vitreous he

126 Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR) are one of the

127 logy recommends that patients diagnosed with proliferative diabetic retinopathy (PDR) be considered f

128 Uncontrolled proliferative diabetic retinopathy (PDR) can cause fibro

129 etters at 2 consecutive visits) or high-risk proliferative diabetic retinopathy (PDR) developed.

130 ndothelial growth factor (VEGF) treatment on proliferative diabetic retinopathy (PDR) development amo

131 cation of patients at risk of progression to proliferative diabetic retinopathy (PDR) enables earlier

132 e macular microvascular changes in eyes with proliferative diabetic retinopathy (PDR) following panre

133 Patients suffering from late-stage proliferative diabetic retinopathy (PDR) had elevated vi

134 iabetic retinopathy (NPDR) was found in 69%, proliferative diabetic retinopathy (PDR) in 31% and adva

135 eviously been reported to be associated with proliferative diabetic retinopathy (PDR) in Caucasian pa

136 ctors for events that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated

137 ovide the real-world outcomes of people with proliferative diabetic retinopathy (PDR) in India and hi

138 Seventy-four eyes with proliferative diabetic retinopathy (PDR) in need of PRP

139 tion (PRP) is a common approach for treating proliferative diabetic retinopathy (PDR) in the clinical

140 The association of proliferative diabetic retinopathy (PDR) interventions o

141 Proliferative diabetic retinopathy (PDR) is a common cau

142 Proliferative diabetic retinopathy (PDR) is a serious mi

143 The hallmark of proliferative diabetic retinopathy (PDR) is retinal neov

144 Panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) may lead to per

145 Areas of neovascularization (NV) in proliferative diabetic retinopathy (PDR) on ultra-widefi

146 oth groups to treat development of high-risk proliferative diabetic retinopathy (PDR) or CI-DME with

147 ry and angiogenic factors from patients with proliferative diabetic retinopathy (PDR) or diabetic mac

148 eated exclusively with anti-VEGF therapy for proliferative diabetic retinopathy (PDR) or nonprolifera

149 y eye centre (Aberdeen Royal Infirmary) with proliferative diabetic retinopathy (PDR) related complic

150 Proliferative diabetic retinopathy (PDR) remains a leadi

151 ascular endothelial growth factor agents for proliferative diabetic retinopathy (PDR) requires that p

152 alogues have been successfully used to treat proliferative diabetic retinopathy (PDR) that is unrespo

153 Some eyes with proliferative diabetic retinopathy (PDR) treated to stab

154 Twenty-nine patients with proliferative diabetic retinopathy (PDR) undergoing pars

155 The standard care for proliferative diabetic retinopathy (PDR) usually is panr

156 roliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) were detected i

157 show that vitreal fluids from patients with proliferative diabetic retinopathy (PDR) were enriched w

158 roliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) were excellent

159 death, eyes with macular hole, and eyes with proliferative diabetic retinopathy (PDR) were investigat

160 For patients with proliferative diabetic retinopathy (PDR) who do not resp

161 retinopathy (PVR) (n = 30), PVR (n = 16) and proliferative diabetic retinopathy (PDR) with tractional

162 elial growth factor (VEGF), in patients with proliferative diabetic retinopathy (PDR) with variable d

163 Patients with stable treated proliferative diabetic retinopathy (PDR) without center-

164 hy (NPDR) without macular edema, 20 eyes had proliferative diabetic retinopathy (PDR) without macular

165 61.7% had an etiology of proliferative diabetic retinopathy (PDR), 23.3% had reti

166 iabetic retinopathy (NPDR), 13 with DME, and proliferative diabetic retinopathy (PDR), and 27 healthy

167 c ischemic optic neuropathy (NAION), treated proliferative diabetic retinopathy (PDR), and branch ret

168 RD), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and proliferat

169 rovascular membranes (FVMs), the hallmark of proliferative diabetic retinopathy (PDR), cause retinal

170 onproliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), or diabetic ma

171 l among eyes with vitreous hemorrhage due to proliferative diabetic retinopathy (PDR), post hoc analy

172 moderate to severe retinopathy, and 28 with proliferative diabetic retinopathy (PDR), previously tre

173 ation (PRP) is the mainstay of treatment for proliferative diabetic retinopathy (PDR), reducing the r

174 In proliferative diabetic retinopathy (PDR), retinal ischem

175 ers have been developed for the treatment of proliferative diabetic retinopathy (PDR), the leading ca

176 pars plana vitrectomy, while in a case with proliferative diabetic retinopathy (PDR), vitrectomy was

177 retinal photocoagulation (PRP) when managing proliferative diabetic retinopathy (PDR), with or withou

178 reous samples from patients with and without proliferative diabetic retinopathy (PDR).

179 nal force generation, activities relevant to proliferative diabetic retinopathy (PDR).

180 abetic retinopathy (NPDR), and diabetic with proliferative diabetic retinopathy (PDR).

181 showing neovascularization in patients with proliferative diabetic retinopathy (PDR).

182 These results are similar to proliferative diabetic retinopathy (PDR).

183 syndrome or retinal neovascularization from proliferative diabetic retinopathy (PDR).

184 SL) in a vitrectomised eye of a patient with proliferative diabetic retinopathy (PDR).

185 ections versus PRP alone in the treatment of proliferative diabetic retinopathy (PDR).

186 cluding retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR).

187 ar endothelial growth factor (anti-VEGF) for proliferative diabetic retinopathy (PDR).

188 ulature could lead to imaging biomarkers for proliferative diabetic retinopathy (PDR).

189 ischemia (DMI) patients with stable treated proliferative diabetic retinopathy (PDR).

190 photocoagulation (PRP) for the treatment of proliferative diabetic retinopathy (PDR).

191 tive diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR).

192 ) on retinal nonperfusion (RNP) in eyes with proliferative diabetic retinopathy (PDR).

193 agulation (PRP) in eyes with treatment-naive proliferative diabetic retinopathy (PDR).

194 with a vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).

195 my (PPV) for severe manifestations of active proliferative diabetic retinopathy (PDR).

196 inopathy (NPDR), and 2.3% for severe NPDR or proliferative diabetic retinopathy (PDR).

197 agulation (PRP) in treatment-naive eyes with proliferative diabetic retinopathy (PDR).

198 nd has been implicated in the progression of proliferative diabetic retinopathy (PDR).

199 redictive role for subsequent development of proliferative diabetic retinopathy (PDR).

200 ar endothelial growth factor plays a role in proliferative diabetic retinopathy (PDR).

201 then thickening as the patient progressed to proliferative diabetic retinopathy (PDR, 295.17 +/- 95.6

202 ignificantly lower in diabetic patients with proliferative diabetic retinopathy (PDR; respectively, 2

203 ages of DR (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]) have a higher

204 plications (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]), which require

205 er non-proliferative diabetic retinopathy or proliferative diabetic retinopathy prevalence.

206 For non-proliferative diabetic retinopathy, preventative afliber

207 has implications in future trial design for proliferative diabetic retinopathy prevention.

208 factor-1 (SDF-1) concentration increases as proliferative diabetic retinopathy progresses.

209 atin (SST) analogues have been used to treat proliferative diabetic retinopathy, pseudotumor cerebri,

210 ommon in eyes with retinal diseases, such as proliferative diabetic retinopathy, retinal vein occlusi

211 Patients with a history of proliferative diabetic retinopathy, retinal venous occlu

212 ty of the primary RD repair, history of PVR, proliferative diabetic retinopathy, serous RD, retinal d

213 In proliferative diabetic retinopathy, steroids may directl

214 In this report, we describe a case of proliferative diabetic retinopathy that developed into e

215 n patients with severe NPDR or non-high-risk proliferative diabetic retinopathy, the same association

216 men; mean [SD] age, 54.8 [14.6] years) with proliferative diabetic retinopathy (there was a 1:1 rati

217 ants whose eyes had vitreous hemorrhage from proliferative diabetic retinopathy, there was no statist

218 020, among 120 treatment-naive patients with proliferative diabetic retinopathy to evaluate the topog

219 deep capillary plexuses in patients with non-proliferative diabetic retinopathy trained on a database

220 Among eyes with proliferative diabetic retinopathy, treatment with ranib

221 Screening tools for non-proliferative diabetic retinopathy using OCT angiography

222 ify neovascularization (NV) in patients with proliferative diabetic retinopathy using swept-source op

223 ompared with diabetes alone, the presence of proliferative diabetic retinopathy was associated with a

224 Progression to proliferative diabetic retinopathy was higher in individ

225 Because retinal hypoxia often precedes proliferative diabetic retinopathy, we have studied the

226 branes surgically removed from patients with proliferative diabetic retinopathy were analyzed by zymo

227 han RRD, previous vitreoretinal surgery, and proliferative diabetic retinopathy were excluded.

228 ously untreated or post-laser treated active proliferative diabetic retinopathy were recruited from 2

229 ho underwent primary vitrectomy for TRD from proliferative diabetic retinopathy were studied.

230 nopathy (including diabetic macular edema or proliferative diabetic retinopathy) were used to test th

231 h vison loss due to vitreous hemorrhage from proliferative diabetic retinopathy who were enrolled fro

232 INTERPRETATION: Patients with proliferative diabetic retinopathy who were treated with